Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

Earnings live: Circle stock soars, First Solar and Lowe's fall on guidance misses

View original at finance.yahoo.com
Earnings live: Circle stock soars, First Solar and Lowe's fall on guidance misses Fourth quarter earnings season is entering its final stretch…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 results were largely in-line with expectations, reflecting lack of storm activity and ongoing consumer uncertainty in housing, with underlying demand relatively stable throughout the year when adjusting for storms

    80% confidence
  • While housing macro remains pressured, company is focused on productivity initiatives and well-positioned to take share regardless of macro environment

    80% confidence
  • Early reaction with shares down low-single digits makes sense with results and guidance in-line to slightly below expectations

    80% confidence
  • Growth journey continued into 2025 with commissioning of Louisiana factory and decision to establish South Carolina facility while maintaining disciplined approach to contracting and pricing certainty

    80% confidence
  • Domino's share on DoorDash expected to grow as awareness and marketing spend increases, representing meaningful opportunity as fair share not yet reached on major aggregators

    80% confidence
  • MORE strategy delivered higher sales and profits, showcasing ability to drive store level profitability while providing incredible value for customers

    80% confidence
  • Adding approximately 1.1 million net new members in 2025 highlights incredible demand for the brand after 50% price increase

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com